 Zynerba Pharmaceuticals Inc NASDAQ:ZYNE said it has presented a poster at the 2022 National Organization for Rare Disorders NORD Rare Diseases and Orphan Products Breakthrough Summit being held October 17-18, 2022, in Washington DC. The poster, titled An Open-Label Tolerability and Efficacy Study of ZYN002 Cannabidiol Administered as a Transdermal Gel to Children and Adolescents with 22q11.2 Deletion Syndrome INSPIRE, reports data from the first 14-week treatment period that suggests a positive risk-benefit profile for Zynerbas cannabidiol-formulated gel Zygel in improving anxiety-related and behavioral symptoms in children and adolescents with 22q11.2 deletion syndrome 22q. 